The complexity of molecular entities in clinical development has increased in recent years. We’ve been fortunate to be involved in the CMC development of some drug candidates that posed some interesting challenges, such as complexity of structure, number of asymmetric centers, length of synthesis, lack of UV chromophore, amphiphilic nature, and so on.
One interesting analyte posed a unique challenge. A large broad unknown HPLC peak appeared chromatograms during its analysis. Since this was an API in development, it was imperative to solve this problem. By considering the analyte’s chemical structure and how it might interact with a sub-ppm impurity in the mobile phase modifier
led us to the answer.
All Rights Reserved | Site by Fix8